Results for: AstraZeneca

A Utah mother, Brianne Dressen, alleges that the pharmaceutical company AstraZeneca breached a contract that promised compensation for injuries sustained during a clinical trial for the COVID-19 vaccine. After experiencing severe adverse effects from the vaccine, Dressen was left with mounting medical bills and claims that AstraZeneca has failed to provide adequate support. The lawsuit, filed in the U.S., is the first of its kind against AstraZeneca regarding the coronavirus vaccine trial. Dressen’s aim is to hold the company accountable and raise awareness about the potential risks associated with clinical trials and the need for proper compensation for participants who suffer injuries.

AstraZeneca’s COVID-19 vaccine, in collaboration with Oxford University, has been found to increase the risk of a rare but deadly blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT). The condition, characterized by the presence of a specific blood autoantibody targeting platelet factor 4 (PF4), was initially observed following the administration of the Oxford-AstraZeneca vaccine, also known as Covishield in India and Vaxzevria in Europe. Researchers have since discovered that PF4 antibodies can also trigger VITT in cases of natural adenovirus infections. AstraZeneca has also announced positive results from a late-stage trial of sipavibart, a long-acting antibody therapy that has shown promise in reducing the risk of infection among immunocompromised individuals.

A group of doctors has expressed concerns over the safety of Covishield vaccine, expressing deep concern over the possibility of blood clots as a rare side effect. They have urged the government to review the science behind all COVID vaccines, audit their commercialization, and implement active surveillance to identify adverse events as early as possible.

AstraZeneca has initiated the withdrawal of its Vaxzevria Covid vaccine globally due to a surplus of available updated vaccines and a decline in demand. The company had earlier admitted that its Covid vaccines may cause Thrombosis Thrombocytopenia Syndrome (TTS) in rare cases, but maintained that the vaccine’s safety and efficacy are supported by extensive clinical trial data and real-world evidence. AstraZeneca has also been facing lawsuits related to alleged vaccine side effects, including a class action lawsuit and cases in India over the Covishield vaccine.

AstraZeneca admits the possibility of blood clots from Covishield vaccines, leading to lawsuits in the UK. Congress leader Rahul Gandhi files for Lok Sabha elections from Raebareli. Ola Cabs CEO resigns, and the company plans to lay off 10% of its workforce. Alphabet lays off its Python team. Adani Ports reports a significant increase in quarterly net profit. FirstCry refiles IPO papers, revealing its financial standing. Prajwal Revanna faces sexual abuse allegations, prompting Karnataka Chief Minister Siddaramaiah to criticize the government’s response. Comedian Shyam Rangeela will challenge Prime Minister Narendra Modi in Varanasi during the Lok Sabha elections. US President Joe Biden suggests that China and India’s economic struggles stem from ‘xenophobia’.

Rashtriya Janata Dal (RJD) leader Misa Bharti has alleged that Prime Minister Narendra Modi’s photo was removed from COVID-19 vaccination certificates due to ongoing concerns regarding the Covishield vaccine. Bharti’s statement follows reports of AstraZeneca admitting that Covishield carries a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS) in court documents in the UK. However, the Ministry of Health and Family Welfare attributed the removal of PM Modi’s photo to the Model Code of Conduct for the Lok Sabha elections. AstraZeneca has emphasized the vaccine’s overall safety profile while reiterating its commitment to patient safety. Meanwhile, Samajwadi Party chief Akhilesh Yadav has criticized the BJP, claiming that people who received the vaccine will vote against the party due to concerns about its safety.

Amidst concerns raised in the UK High Court, a prominent medical expert in India has urged the government to investigate cases of adverse reactions to COVID-19 vaccines. Dr. Sanjay Rai, a key figure in India’s pandemic response, called for a review by the health ministry’s Adverse Event Following Immunization (AEFI) committee. While acknowledging the effectiveness of vaccines in mitigating COVID-19 severity, Dr. Rai emphasized the importance of evaluating rare side effects like thrombocytopenia syndrome (TTS). The plea for an expert panel to assess side effects has been filed in the Supreme Court of India, mirroring a class action lawsuit in the UK.

The Oxford-AstraZeneca COVID vaccine has been associated with a rare blood clot disorder known as Thrombotic Thrombocytopenia Syndrome (TTS). This disorder, while uncommon, involves the formation of blood clots accompanied by a low platelet count. Despite the low incidence rate, the risk of TTS remains a concern, particularly given the widespread administration of the vaccine.

AstraZeneca is facing a class action lawsuit in the UK over claims that its Covishield vaccine caused deaths and severe injuries in several cases. Victims in as many as 51 cases in the UK High Court are seeking damages up to 100 million pounds. AstraZeneca has contested the claims, but admitted in court documents that Covishield can, in very rare cases, cause Thrombosis with Thrombocytopenia Syndrome (TTS), which leads to blood clots and low blood platelet count.

Pharmaceutical giant AstraZeneca has admitted that its Covid-19 vaccine can cause a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS). The admission was made in court documents for the first time since the vaccine was rolled out. The company, which developed the vaccine in partnership with the University of Oxford, is facing a class-action lawsuit alleging that their vaccine has resulted in fatalities and serious injuries among recipients. Victims and grieving relatives are seeking damages estimated to be worth up to £100 million.